The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...